Tradipitant Patent Expiration
Tradipitant was first introduced by Vanda Pharmaceuticals Inc
Tradipitant Patents
Given below is the list of patents protecting Tradipitant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nereus | US12318375 | Method Of Treatment With Tradipitant | Aug 09, 2036 | Vanda Pharms Inc |
| Nereus | US10772880 | Method Of Treatment With Tradipitant | Mar 04, 2036 | Vanda Pharms Inc |
| Nereus | US10821099 | Use Of Tradipitant In Motion Sickness | Mar 04, 2036 | Vanda Pharms Inc |
| Nereus | US11324735 | Method Of Treatment With Tradipitant | Mar 04, 2036 | Vanda Pharms Inc |
Tradipitant's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tradipitant:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis | Vanda Pharmaceuticals | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| Tradipitant for Functional Dyspepsia | Xiao Jing (Iris) Wang | NA |
ENROLLING BY INVITATION
(Jul 1, 2026)
| PHASE2 |